Edwards Lifesciences (NYSE:EW) Raised to Buy at Stifel Nicolaus

Stifel Nicolaus upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a research report report published on Thursday morning, MarketBeat.com reports. Stifel Nicolaus currently has $90.00 price target on the medical research company’s stock, up from their previous price target of $75.00.

Several other analysts have also issued reports on the stock. Barclays increased their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research report on Monday, December 2nd. The Goldman Sachs Group boosted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Piper Sandler reduced their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 11th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and a consensus price target of $79.19.

Edwards Lifesciences Stock Up 2.8 %

Shares of EW opened at $73.15 on Thursday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The firm’s 50 day moving average is $72.40 and its 200-day moving average is $70.07. The stock has a market capitalization of $43.14 billion, a PE ratio of 10.56, a P/E/G ratio of 3.65 and a beta of 1.11.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,000 shares of company stock valued at $2,195,180. 1.29% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences during the 3rd quarter valued at about $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences in the 4th quarter worth about $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences in the third quarter worth approximately $32,000. Avior Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Peoples Bank KS bought a new position in shares of Edwards Lifesciences during the third quarter valued at $40,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.